Discovery of Highly Polar β-homophenylalanine Derivatives as Non-systemic Intestine-Targeted Dipeptidyl Peptidase IV Inhibitors.

Although intensively expressed within intestine, the precise roles of intestinal dipeptidyl peptidase IV (DPPIV) in numerous pathologies remain incompletely understood. Here, we first reported a nonsystemic intestine-targeted (NSIT) DPPIV inhibitor with beta-homophenylalanine scaffold, compound 7, which selectively inhibited the intestinal rather than plasmatic DPPIV at an oral dosage as high as 30 mg/kg. We expect that compound 7 could serve as a qualified tissue selective tool to determine undetected physiological or pathological roles of intestinal DPPIV.